Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IADSA on health claims

This article was originally published in The Tan Sheet

Executive Summary

Relying solely on human intervention studies to substantiate health claims is impractical and the Codex Alimentarius recommendations for the scientific basis of health claims should take into account the totality of evidence, the International Alliance of Dietary/Food Supplement Associations says. The draft of the recommendations states human trials are the prime source of evidence to back health claims and "makes no reference to evidence based on traditional knowledge and history of use," IADSA says. While human trials are important, they are only one source of information and "all sources of scientific data have inherent limitations, hence the need to focus on the totality of the available data and weighing of the evidence," says David Richardson, scientific adviser to the U.K. Council for Responsible Nutrition and IADSA. CRN and other members of the supplement and nutrition industry have long protested the pharmaceutical model of testing nutrients (1"The Tan Sheet" May 7, 2007, p. 12)...

You may also be interested in...



Supplement Firms Should Value RCTs, But Also Improve Other Research – CRN

Supplement firms must adapt clinical research methods to accommodate the industry's unique challenges and gain acceptance from mainstream medicine, Council for Responsible Nutrition President and CEO Steve Mister said during the trade group's Day of Science workshop May 3

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel